Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-26T21:37:16.741Z Has data issue: false hasContentIssue false
  • English
  • Français

Evaluating the use of external beam radiation alone in the management of cervix cancer

Published online by Cambridge University Press:  27 June 2017

Thuraya Al-Hajri ,
Naghmeh Isfahanian ,
Najlaa Alyamani ,
Soha Atallah ,
E. Choan ,
Tien Le  and
Rajiv Samant
Thuraya Al-Hajri*
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
Naghmeh Isfahanian
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
Najlaa Alyamani
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
Soha Atallah
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
E. Choan
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
Tien Le
Affiliation:
Division of Gynecology Oncology, The Ottawa Hospital, Ottawa, ON, Canada
Rajiv Samant
Affiliation:
Division of Radiation Oncology, The Ottawa Hospital, Ottawa, ON, Canada
*
Correspondence to: Thuraiya Al-Hajri, Division of Radiation Oncology, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, Canada, K1H 8L6. Tel: +1 613 798 5555, Ext. 70241. Fax: +1 613 247 3511. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

To determine the outcome of patients with locally advanced cervix cancer treated with curative intent using external beam radiotherapy (EBRT), without brachytherapy.

Materials and methods

A chart review was performed of all patients with cervix cancer who received EBRT alone at our centre from 2000 to 2010. Overall survival and local control were evaluated using Kaplan–Meier survival curves.

Results

In total, 22 patients were identified. The median age and follow-up were 56 years and 65 months, respectively. The stage included IB to IVB. Main histology was squamous cell carcinoma (82%). Median tumour size was 5·5 cm. Majority treated with 3D conformal techniques and nine patients (41%) were treated with intensity-modulated radiation therapy (IMRT); 14 patients received doses of ≥65 Gy. Most patients (73%) received weekly concurrent cis-platinum. The major reason for not receiving brachytherapy was locally extensive tumour (59%). The 5-year relapse-free survival and overall survival rates were 57 and 50%, respectively. Seven patients (32%) had a component of loco-regional failure, mainly within the cervix. There was a better outcome among the nine patients treated with IMRT to a median dose of 66 Gy with a loco-regional control of 78%.

Conclusions

Patients who cannot have brachytherapy may still achieve acceptable rates of loco-regional disease control if high radiation doses (>65 Gy) was delivered.

Keywords

brachytherapycervix cancerIMRToutcomesradiotherapy
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 17 , Issue 1 , March 2018 , pp. 37 - 43
Check for updates
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Pisani, P, Parkin, D M, Muñoz, N, Ferlay, J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997; 6: 387–400.Google ScholarPubMed
2. Canadian-Cancer Statistic. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society, 2014. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014-EN.pdf.Google Scholar
3. Parkin, D M, Bray, F, Ferlay, J, Pisani, P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–159.CrossRefGoogle ScholarPubMed
4. Barbera, L, Thomas, G. Management of early and locally advanced cervical cancer. Semin Oncol 2009; 36: 155–169.Google Scholar
5. Au‐Yeung, G, Mileshkin, L, Bernshaw, D M, Kondalsamy‐Chennakesavan, S, Rischin, D, Narayan, K. Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer center. J Med Imaging Radiat Oncol 2013; 57: 97–104.Google Scholar
6. Rose, P G, Bundy, B, Watkins, E B et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–1153.Google Scholar
7. Loizzi, V, Cormio, G, Loverro, G, Selvaggi, L, Disaia, P J, Cappuccini, F. Chemoradiation: a new approach for the treatment of cervical cancer. Int J Gynecol Cancer 2003; 13: 580–586.CrossRefGoogle ScholarPubMed
8. King, M, McConkey, C, Latief, T N, Hartley, A, Fernando, I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin Oncol 2006; 18: 38–45.CrossRefGoogle ScholarPubMed
9. Dueñas-Gonzalez, A, Cetina, L, Mariscal, I, de la Garza, J. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev 2003; 29: 389–399.CrossRefGoogle ScholarPubMed
10. Green, J A, Kirwan, J M, Tierney, J F et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781–787.CrossRefGoogle ScholarPubMed
11. Chereau, E, Hosserye, C, Ballester, M et al. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer. Anticancer Res 2013; 33: 1661–1666.Google ScholarPubMed
12. Nag, S, Erickson, B, Thomadsen, B et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48: 201–211.Google Scholar
13. Viswanathan, A N, Beriwal, S, De Los Santos, J et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 2012; 11: 47–52.Google Scholar
14. Okuma, K, Yamashita, H, Kobayashi, R, Nakagawa, K. A study of high-dose-rate intracavitary brachytherapy boost for curative treatment of uterine cervical cancer. J Contemp Brachytherapy 2015; 7: 128–134.CrossRefGoogle ScholarPubMed
15. Teke, F, Yoney, A, Teke, M et al. Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. Contemp Oncol 2015; 7: 130–136.Google Scholar
16. Lee, L J, Das, I J, Higgins, S A et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy 2012; 11: 53–57.CrossRefGoogle ScholarPubMed
17. Nakano, T, Kato, S, Ohno, T et al. Long‐term results of high‐dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 2005; 103: 92–101.CrossRefGoogle ScholarPubMed
18. https://webcache.googleusercontent.com/search?q=cache:D1dfShq-8GUJ:https://www.sciencedaily.com/releases/2013/09/130911125057.htm+&cd=1&hl=en&ct=clnk&gl=uk. Accessed on 11th September 2013.Google Scholar
19. https://www.cms.gov/medicare-coveragedatabase. Accessed on 9th July 2015.Google Scholar
20. Coia, L, Won, M, Lanciano, R, Marcial, V A, Martz, K, Hanks, G. The patterns of care outcome study for cancer of the uterine cervix results of the second national practice survey. Cancer 1990; 66: 2451–2456.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
21. Sturdza, A, Potter, R, Fokdal, L U et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicentre cohort study. Radiother Oncol 2016; 120: 428–433.Google Scholar
22. Georg, D, Kirisits, C, Hillbrand, M, Dimopoulos, J, Pötter, R. Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 2008; 71: 1272–1278.Google Scholar
23. Jagsi, R, Abrahamse, P, Hawley, S T, Graff, J J, Hamilton, A S, Katz, S J. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 2012; 118: 333–341.Google Scholar
24. Viswanathan, A N, Thomadsen, B. American Brachytherapy Society Cervical Cancer Recommendations Committee: American Brachytherapy Society: American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 2012; 11: 33–46.Google Scholar
25. Petereit, D G, Frank, S J, Viswanathan, A N. Brachytherapy: where has it gone? J Clin Oncol 2015; 33: 980–982.Google Scholar
26. Han, K, Milosevic, M, Fyles, A, Pintilie, M, Viswanathan, A N. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biolo Phys 2013; 87: 111–119.CrossRefGoogle ScholarPubMed
27. Chen, C C, Lin, J C, Jan, J S, Ho, S C, Wang, L. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecol Oncol 2011; 122: 9–13.CrossRefGoogle ScholarPubMed
28. Karlsson, J, Dreifaldt, A C, Mordhorst, L B, Sorbe, B. Differences in outcome for cervical cancer patients treated with or without brachytherapy. Brachytherapy 2017; 16: 133–140.Google Scholar
29. Liu, Y, Yu, J, Qian, L, Zhang, H, Ma, J. Extended field intensity-modulated radiotherapy plus concurrent nedaplatin treatment in cervical cancer. Oncol Lett 2016; 11: 3421–3427.CrossRefGoogle ScholarPubMed
30. Haas, J A, Witten, M R, Clancey, O, Episcopia, K, Accordino, D, Chalas, E. CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy. Front Oncol 2012; 2: 25–30.CrossRefGoogle ScholarPubMed
31. Mundt, A J, Mell, L K, Roeske, J C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biolo Phys 2003; 56: 1354–1360.CrossRefGoogle ScholarPubMed